CCM
VRTX icon

Cadian Capital Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Cadian Capital Management’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-75,000
Closed -$5.96M – 62
2016
Q1 		$5.96M Hold
75,000
– – 0.4% 39
2015
Q4 		$9.44M Hold
75,000
– – 0.34% 60
2015
Q3 		$7.81M Buy
+75,000
New +$9.64M 0.28% 61

Other funds holding VRTX

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Cadian Capital Management's VRTX Position: Q2 2016 in Review

Cadian Capital Management sold out of Vertex Pharmaceuticals (VRTX) in Q2 2016, closing a stake of 75,000 shares — an estimated $5.96M sold.

Cadian Capital Management first reported a position in VRTX in Q3 2015 and held it in 3 quarters. The position peaked at $9.44M in Q4 2015. 482 funds tracked by Wall St. Rank hold VRTX as of Q2 2016.

  • Cadian Capital Management reported no remaining Vertex Pharmaceuticals position as of Q2 2016 after selling out during the quarter.
  • Cadian Capital Management sold 75,000 Vertex Pharmaceuticals shares in Q2 2016, an estimated $5.96M.
  • Cadian Capital Management first reported a position in Vertex Pharmaceuticals in Q3 2015 and held it in 3 quarters.
  • Cadian Capital Management's Vertex Pharmaceuticals position peaked at $9.44M in Q4 2015.
  • 482 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2016.

Based on Cadian Capital Management's 13F filing for Q2 2016, filed 12 Aug 2016.